Learn more about the top news stories of the week in our round-up, including new guidance for drug-resistant infections and a Phase I trials for a MERS treatment.
Browsing: Clinical Trial
A newly-developed single-dose cholera vaccine has shown promise in clinical trials, suggesting it could provide faster protection and control outbreaks more rapidly than the standard regimen.
Researchers have investigated the safety and virologic effect of an HIV booster vaccine in infected individuals on antiretroviral therapy during acute or early infection. Although no beneficial effects were determined, the study provides much needed insights for future efforts.
Results for Phase I Zika vaccine trials have recently demonstrated that both a gene-based and an inactivated virus vaccine appear to be safe and immunogenic.
To date there have only been a handful of Phase III efficacy trials for HIV vaccine candidates, which have had varied, and in some cases controversial, results. Here we review the history of HIV vaccine efficacy studies and look into the vaccine candidates closest to front-line use.
In this infographic we summarize the clinical candidates reported by the WHO – indicating which diseases they are active (or possibly active) against, whether they’re considered innovative and which Phase the trials are currently in.
In line with our focus this month on all aspects of influenza, we spoke to Ed Schmidt, project manager of the Universal Influenza Vaccines Secured (UNISEC) consortium, about its aim to develop a universal flu vaccine.
Researchers have reported an acceptable safety and immunogenicity profile of an Ebola vaccine in adults and potentially in children in Africa – indicating that the vaccine produces an immune response and is considered safe.
A new DNA-based Zika vaccine, GLS-5700, has been reported as safe and immunogenic in Phase I trial, according to new research.
Editor, Martha Powell, discusses the issues around the current guidance for treating HAT and gives an overview of the current clinical pipeline being spearheaded by the Drugs for Neglected Diseases initiative.